This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alcon (ALC) Gains From Robust Contact Lense Sales, Launches
by Zacks Equity Research
In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.
Haemonetics (HAE) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
Haemonetics (HAE) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
Haemonetics (HAE) Surges 5.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Align Technology's (ALGN) New Pacts, Innovation Aid Growth
by Zacks Equity Research
Align Technology's (ALGN) Invisalign comprehensive witnesses strong initial adoption in the market.
Labcorp (LH) Completes Strategic Deal With Jefferson Health
by Zacks Equity Research
Labcorp's (LH) agreement with Jefferson to build academic collaborations around teaching and developing innovative tests.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
New product developments and the pending NuVasive acquisition raise optimism about the Globus Medical (GMED) stock.
Quest Diagnostics (DGX) Brings New Test for Prostate Cancer
by Zacks Equity Research
Quest Diagnostics (DGX) collaborates with Envision Sciences to bring a novel prosate cancer biomarker test.
Does Haemonetics (HAE) Have the Potential to Rally 25% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
by Zacks Equity Research
Here is how Alkermes (ALKS) and Haemonetics (HAE) have performed compared to their sector so far this year.
Labcorp (LH) Inks Asset Acquisition Deal With Legacy Health
by Zacks Equity Research
Labcorp's (LH) new agreement with Legacy Health will broaden access to its Diagnostics capabilities and improve services.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about QIAGEN (QGEN) backed by the performance of the NGS portfolio and diagnostic solutions.
Tandem Diabetes (TNDM) Gets FDA Nod for Tandem Mobi System
by Zacks Equity Research
Tandem Diabetes (TNDM) receives FDA clearance for the world's smallest AID system, Tandem Mobi.
Penumbra (PEN) Gains on New Launches Amid Currency Headwind
by Zacks Equity Research
Penumbra's (PEN) ability to improve net gross margins and EPS amid ongoing inflationary pressure and supply-chain headwinds buoy optimism.
Edwards' (EW) Innovation Aids Growth, Critical Care Flourishes
by Zacks Equity Research
Edwards' (EW) Surgical Structural Heart sales growth is lifted by the increased adoption of its premium products across all regions.
Sensus Healthcare (SRTS) Expands Global Base With New Pact
by Zacks Equity Research
The agreement includes the distribution of Sensus Healthcare's (SRTS) SRT-100, SRT-100+ and SR-100 Vision systems, specifically designed for the treatment of non-melanoma skin cancer and keloids.
Bruker (BRKR) Showcases UK Science Investments at EUROMAR 2023
by Zacks Equity Research
Bruker (BRKR) begins advanced life-science and green-tech research in the United Kingdom.
Quanterix (QTRX) Advances in Alzheimer's Diagnosis With LucentAD
by Zacks Equity Research
Quanterix (QTRX) LucentAD biomarker blood test aims to assist healthcare providers in evaluating patients who show cognitive symptoms consistent with the early signs of AD.
Thermo Fisher (TMO) Announces the Acquisition of CorEvitas
by Zacks Equity Research
Thermo Fisher's (TMO) acquisition of CorEvitas is likely to strengthen its value proposition.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.
ResMed (RMD) Expands Solutions Portfolio With Somnoware Buyout
by Zacks Equity Research
ResMed (RMD) announces the acquisition of the Somnoware diagnostic management platform.
Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker
by Zacks Equity Research
Abbott (ABT) receives FDA approval for the AVEIR DR leadless pacemaker system, featuring the proprietary i2i technology.
Teleflex's (TFX) Urolift Global Expansion Aids Amid Cost Woes
by Zacks Equity Research
Teleflex's (TFX) vascular and interventional access product portfolios witness accelerated growth following the $976-million acquisition of Vascular Solutions.
Labcorp (LH) Announces Completion of the Fortrea Spin-off
by Zacks Equity Research
Labcorp (LH) completes the planned spin-off of Fortrea to operate as an independent clinical development business.
Canopy Growth (CGC) Improves Liquidity With Another Selloff
by Zacks Equity Research
Canopy Growth's (CGC) decision to divest facilities aligns with its organizational transformation plan.